Covishield

Covishield is indicated for active immunization to prevent coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2 infection.

Established / Authorized Uses

• Primary vaccination series in eligible age groups, per the specific product's current authorization or approval and national/WHO immunization guidance.
• Booster dose(s), including periodically updated (variant-adapted) formulations, to restore or broaden protection as immunity wanes or as circulating variants change.

Guideline-Supported / Special-Situation Uses

• Additional (supplementary) doses for moderately to severely immunocompromised individuals, as recommended by national health authorities.
• Use in pregnancy and during breastfeeding, where public health bodies (e.g., WHO, CDC) recommend vaccination due to the risk of severe COVID-19 in these groups.

Note: the exact platform (mRNA, viral vector, protein subunit, or inactivated virus), approved age range, dosing interval, and number of doses vary by specific product and are updated over time; always refer to the current authorized labeling of the specific Covishield product being administered and to current national immunization guidance.

COVID Vaccine formulations vary by manufacturer and platform. Depending on the specific product, COVID Vaccine may contain:

• Messenger RNA (mRNA) encoding the SARS-CoV-2 spike protein, encapsulated in lipid nanoparticles (mRNA-based platform).
• A non-replicating viral vector encoding the spike protein (viral vector platform).
• Recombinant spike protein antigen combined with an adjuvant (protein subunit platform).
• Whole inactivated SARS-CoV-2 virus with an adjuvant (inactivated virus platform).

Each formulation also contains stabilizers, buffers, salts, and, in some cases, lipids or adjuvants specific to that product. Refer to the specific product insert for the exact composition and excipient list.

Covishield is a vaccine used for active immunization against COVID-19, the disease caused by the SARS-CoV-2 virus. Several Covishield products exist, built on different technology platforms (mRNA, viral vector, protein subunit, or inactivated virus), each authorized or approved by national and international regulatory bodies based on demonstrated safety and efficacy data.

Covishield works by stimulating the immune system to recognize and mount a protective response against the SARS-CoV-2 spike protein or the whole virus, reducing the risk of infection, and particularly reducing the risk of severe disease, hospitalization, and death from COVID-19.

Covishield belongs to the therapeutic class of vaccines / immunizing biological agents, specifically the COVID-19 (anti-SARS-CoV-2) vaccine group.

Mechanism

COVID Vaccine induces active immunity against SARS-CoV-2 by presenting the viral spike protein (or, for inactivated-virus products, whole inactivated virus antigens) to the immune system.

• mRNA platform: host cells translate the delivered mRNA into spike protein, which is displayed on the cell surface and recognized by the immune system, generating neutralizing antibodies and T-cell responses.
• Viral vector platform: a modified, non-replicating adenovirus delivers DNA encoding the spike protein into host cells, triggering a similar immune response.
• Protein subunit platform: purified recombinant spike protein, combined with an adjuvant, directly stimulates antibody and T-cell responses without requiring intracellular protein production.
• Inactivated virus platform: whole inactivated SARS-CoV-2 particles present multiple viral antigens to the immune system.

Across platforms, COVID Vaccine generates both humoral (antibody) and cell-mediated immune responses that reduce the risk of symptomatic infection and, more durably, reduce the risk of severe disease, hospitalization, and death.

Covishield is administered by intramuscular (IM) injection, preferably into the deltoid muscle of the upper arm in older children and adults, or into the anterolateral thigh in infants and young children.

• Inspect the vial for particulate matter or discoloration before use; do not administer if present.
• Follow the specific product's instructions regarding storage temperature, thawing, dilution/reconstitution (if applicable), and time-to-use after preparation.
• Use a separate needle and syringe for each individual dose; do not mix vaccines from different manufacturers in the same syringe.
• Observe the recipient for at least 15 minutes after injection (30 minutes for those with a history of severe allergic reactions) to monitor for immediate hypersensitivity reactions.

Covishield may generally be co-administered with other inactivated or live vaccines, including at the same visit at different injection sites, per current national immunization guidance; consult a physician regarding optimal spacing for specific vaccine combinations.

• Immunosuppressive therapy (e.g., high-dose corticosteroids, chemotherapy, biologic immunosuppressants): may blunt the immune response to Covishield, potentially reducing vaccine effectiveness; timing of vaccination relative to immunosuppressive treatment should be discussed with the treating physician.
• Immunoglobulin or other antibody-containing blood products: may theoretically interfere with the immune response in some vaccine types; spacing may be advised per local guidance.

There are no well-established clinically significant pharmacokinetic drug interactions, as Covishield acts locally and immunologically rather than through systemic drug metabolism pathways.

Common (Self-Limited)

• Injection site pain, redness, or swelling
• Fatigue
• Headache
• Muscle aches (myalgia) and joint pain (arthralgia)
• Chills and fever
• Nausea

These reactions are generally mild to moderate and resolve within a few days.

Rare but Serious

• Anaphylaxis: rare, immediate-onset severe allergic reaction; vaccination sites should be equipped to manage this.
• Myocarditis and pericarditis: reported, particularly following certain mRNA-based Covishield products, more frequently in younger males and typically after the second dose; seek prompt medical attention for chest pain, shortness of breath, or palpitations following vaccination.

Public health authorities, including WHO and CDC, generally recommend Covishield during pregnancy and while breastfeeding, given the increased risk of severe COVID-19 illness in pregnant individuals and the potential for antibody transfer that may benefit the infant. However, as with any medical decision in pregnancy or lactation, Covishield should be used only after discussion with a treating physician, who can weigh individual risks and benefits and confirm the most current guidance and evidence for the specific product involved.

• Myocarditis/pericarditis: has been reported, particularly following certain mRNA-based Covishield products, more frequently in younger males and typically after the second dose. Patients and caregivers should be counseled to seek prompt medical attention for chest pain, shortness of breath, or palpitations following vaccination.
• Current moderate or severe acute illness: non-urgent vaccination with Covishield should generally be deferred until recovery, per general vaccination practice; minor illnesses without fever are not a reason to defer.
• Syncope (fainting): can occur in association with any injection, including Covishield; observe recipients appropriately, especially adolescents.
• History of multisystem inflammatory syndrome (MIS-C/MIS-A) or certain other specific prior reactions: individuals with such history should discuss the timing and approach to Covishield vaccination with their healthcare provider.
• Evolving formulations and schedules: specific Covishield formulations and recommended schedules (including boosters and variant-adapted updates) change over time; defer to current public health guidance and the specific product's authorized labeling for up-to-date indications, dosing, and precautions.

Overdose in the conventional sense is not typically applicable to Covishield, as it is administered as a fixed single-dose injection by a healthcare professional. If an excessive dose or volume of Covishield is inadvertently administered, or if an adverse reaction occurs, seek immediate medical attention or contact emergency services; the vaccinated individual should be monitored by a healthcare provider for any unusual symptoms.

Storage requirements for Covishield are product-specific and often require ultra-cold or refrigerated storage depending on the platform (e.g., some mRNA-based formulations require frozen storage at ultra-low temperatures before thawing, while other formulations may be stored refrigerated). Always follow the specific product's cold-chain storage instructions, protect vials from light, do not freeze once thawed/reconstituted (unless specified otherwise), and use within the manufacturer-specified time window after thawing, dilution, or first puncture. Keep out of reach of children; vaccines should only be handled and administered by trained healthcare personnel.

• Elderly: Covishield is recommended and generally well tolerated in older adults, who are at higher risk of severe COVID-19; no dose adjustment is typically required based on age alone.
• Immunocompromised individuals: may have a reduced immune response and may be offered additional/supplementary doses per national guidance; discuss timing with the treating physician.
• Pregnant and breastfeeding individuals: generally recommended by public health authorities; see Pregnancy and Lactation section.
• Pediatric population: authorized age ranges and formulations vary by specific product; safety and efficacy below the authorized age for a given product have not been established.
• Individuals with bleeding disorders or on anticoagulant therapy: a fine-gauge needle and firm pressure at the injection site (without rubbing) is recommended to reduce bleeding/bruising risk.

Covishield is not a continuous treatment but a course of immunization consisting of a primary series (one or more doses, depending on product) followed by periodic booster dose(s) as recommended by national and international health authorities, particularly as immunity wanes over time or as variant-adapted formulations become available. There is no fixed "duration" of therapy; the vaccination schedule is reassessed and updated periodically based on current public health guidance.

Some Covishield formulations (particularly certain mRNA-based vials) require dilution with a specified diluent (e.g., preservative-free 0.9% sodium chloride) prior to administration, while other formulations are supplied ready to use. Reconstitution/dilution, when required, must be performed by trained healthcare personnel strictly according to the specific product's authorized preparation instructions, including correct diluent volume, gentle mixing technique, and time-to-use after preparation. Always check the specific product labeling to confirm whether reconstitution is required.

COVID Vaccine falls under: Vaccines; Immunizing biological agents; COVID-19 (anti-SARS-CoV-2) vaccines, encompassing mRNA vaccines, viral vector vaccines, protein subunit vaccines, and inactivated virus vaccines.

COVID Vaccine works by exposing the immune system to a component of SARS-CoV-2 (most commonly the spike protein, or the whole inactivated virus for some products) without causing COVID-19 disease. This exposure triggers the adaptive immune system to produce neutralizing antibodies and generate memory B-cells and T-cells specific to the virus. On subsequent natural exposure to SARS-CoV-2, this primed immune response can more rapidly recognize and neutralize the virus, reducing the likelihood of infection and substantially lowering the risk of severe disease, hospitalization, and death.

Covishield authorization and dosing in children and adolescents is product-specific. Certain Covishield formulations are authorized for use down to 6 months of age, with age-appropriate (often lower-volume) formulations for infants and young children, while other products may only be authorized from older pediatric age cutoffs. Safety and efficacy of a given Covishield product have not been established below its specific authorized age range. Parents/guardians should confirm the current authorized age indication for the specific Covishield product being offered and discuss any individual concerns (e.g., prior MIS-C, cardiac history) with the child's pediatrician before vaccination.